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Background: The Head and Neck Cancer Working Group of Swiss Group for Clinical
Cancer Research (SAKK) has investigated the level of consensus (LOC) and discrepancy
in everyday practice of diagnosis and treatment in head and neck cancer.
Materials and Methods: An online survey was iteratively generated with 10 Swiss
university and teaching hospitals. LOC below 50% was defined as no agreement, while
higher LOC were arbitrarily categorized as low (51–74%), moderate (75–84%), and
high (≥85%).
Results: Any LOC was achieved in 62% of topics (n = 60). High, moderate, and low
LOC were found in 18, 20, and 23%, respectively. Regarding Head and Neck Surgery,
Radiation Oncology, Medical Oncology, and biomarkers, LOC was achieved in 50, 57,
83, and 43%, respectively.
Conclusions: Consensus on clinical topics is rather low for surgeons and
radiation oncologists. The questions discussed might highlight discrepancies, stimulate
standardization of practice, and prioritize topics for future clinical research.
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INTRODUCTION
This is the fourth part of the article “A Review of Controversial
Issues in the Management of Head and Neck Cancer: A Swiss
Multidisciplinary andMulti-Institutional Patterns of Care Study,”
providing the results for the items concerning biomarkers, each
followed by a short discussion if deemed relevant. The details of
the methodology is presented in the first part of this series.
RESULTS AND DISCUSSION OF
BIOMARKERS WITH CURRENT
POTENTIAL USE
â Imaging findings indicating hypoxia and/or central necrosis
are not standard factors influencing the treatment decision:
no consensus.
In 5/10 centers, imaging findings indicating hypoxia or central
necrosis affects the decision for the primary treatment modality.
According to the literature (1), tumor hypoxia can be associated
with aggressive tumor phenotype affecting the natural course
of disease in these patients (2) due to assumed radiotherapy
resistance. Based on laboratory experience, a up to three times
higher photon radiation dose is needed to cause the same
cytotoxic effect in hypoxic cells compared to normal tumor cells
(3). Whether such dose escalation could be performed, while
keeping low toxicity rates in normal tissue is questionable (4).
The advantage of dose escalation to hypoxic sub-volumes with
conventional photon radiation has been analyzed in clinical
practice to overcome this bad prognostic factor (5–8). However,
the clinical identification, measurement, and localization of
hypoxia in tumors remain debatable. The studies range from non-
invasive clinical assumptions to direct measurements with oxygen
electrodes, and indirect methods such as serum biomarkers
or immunohistochemistry (IHC) of hypoxia-related markers.
There has been found a significant heterogeneity in regional
oxygenation as well as in biological response to hypoxia
confounding these tissue-sampling methods. In current clinical
practice, boost dose is guided by CT scans and is based
primarily on size criteria (1). However, the correlation between
tumor hypoxia and common clinical parameters such as size,
morphology, and histology is scarce (9). PET scans could deliver
more functional information based on tumor metabolism (10).
In tumors with presence of diffuse hypoxia a systemic
approach using a hypoxic cell cytotoxin or anti-growth factor
drugs might be beneficial to overcome the limitations of hypoxia
(11). Alternatively, in a more focal hypoxia a local/regional
approach, such as IMRT-based radiation dose escalation to
the hypoxic sub-volume might be more successful (12, 13).
In different studies, the complementary role of radiation and
systemic hypoxia-specific pro-drugs to overcome the hypoxia-
induced resistance has been established (14, 15). Furthermore,
there is a higher risk for persistence of hypoxic tumors after
primary CRT and the timing of salvage surgery such as planned
neck dissection should be adapted.
Anyhow, regarding the limited evidence for the role of
imaging findings indicating hypoxia, it is quite remarkable
that half of the centers in Switzerland integrate them in
treatment decisions.
â De-differentiation grade is not a standard factor influencing
the treatment decision: no consensus.
De-differentiation grade of tumors also influences treatment
decision in 5/10 centers. This question did not differ between
squamous cell cancer and other malignancies of the head
and neck.
In salivary gland carcinoma, the histologic grade is a significant
predictor of treatment response and an established factor for
therapeutic decisions, but due to the rarity and wide variety of
different tumor types the definition of predictive grading schemes
is challenging (16).
In HNSCC, histologic grade is not part of the current
staging criteria, probably because its prognostic impact remains
controversial. Weijers et al. (17) found no significant correlation
between grade and prognosis in early stage oral cancer. In
contrast, other studies (18–20) found a significant impact of
tumor differentiation and staging on recurrence and overall
survival. Furthermore, a recent study (21) in early stage oral
cancer has demonstrated a strong association between histologic
grade and survival. High histologic grade was associated with
poorer survival and carried an independent prognostic value
in addition to tumor size, node status, and presence of distant
metastasis (TNM) stage (21). Even though grade is not part of the
UICC staging system, some centers do consider high grade as an
indication for adjuvant treatment (22, 23).
â Determining the HPV status is a standard practice in
oropharyngeal squamous cell carcinoma (OPSCC): high
LOC (100%).
â There is no standard method established for the definition of
HPV status: no consensus.
All (10/10) centers regularly determine the HPV status in
OPSCC. The definition of an HPV attributable tumor is IHC
overexpression of p16 as a single marker (5 centers), HPV high-
risk type DNA positivity by polymerase chain reaction (PCR) (2
centers); HPV high risk type DNA positivity by ISH (1 center)
and p16, followed by PCR if needed according to College of
American Pathologists guidelines (1 center).
The survey was performed prior to the release of the 8th edition
of the UICC TNM classification system, implementing p16 IHC
as a crucial biomarker for staging of OPSCC. Nevertheless, all
centers had already started to routinely determine the HPV-
status in OPSCC. Interestingly, the definition of a positive HPV-
status widely differs between the centers, reflecting the lack
of a worldwide-accepted consensus for the accurate definition
of an HPV-driven cancer. In the new UICC staging system
(8th edition), p16 is accepted for practical and cost-related
reasons considering the guideline to be international (24), but the
definition of a high-risk HPV-attributed cancer is still a matter of
debate (25).
Currently, detection of p16INK4A (inhibitor of cyclin-
dependent kinase 4) overexpression in tumor tissue by IHC
is used as a surrogate marker for HPV-driven HNSCC (26).
However, p16INK4A IHC as a single diagnostic marker has shown
insufficient sensitivity (27–30) and specificity (27, 29–31).
Due to its high sensitivity, high-risk HPV-DNA detection
by quantitative PCR has been commonly employed to detect
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HPV-driven tumors, but was found to lack sufficient specificity,
which could lead to false positive results (32). Indeed, HPV-
DNA detection in tumor specimens is not proving a causal
viral association of carcinogenesis but could also be the result
of a past non-transforming HPV-infection or contamination
(33). Detection of the transcripts of viral oncogenes E6 and
E7 in tumor through mRNA techniques is widely accepted as
gold standard for determining the oncogenic role of HPV in
tumor. However, extraction techniques and analyses of RNA
from the routinely available formalin-fixed paraffin-embedded
tissue specimens remain challenging and costly, limiting their
widespread use (27). In this context, Smeets et al. (31) validated
an algorithm based on the combination of p16INK4A IHC followed
by HPV-DNA analysis to detect an oncogenically active HPV
infection in formalin-fixed paraffin-embedded tissue specimens:
the accuracy, sensitivity, and specificity were 98, 96, and 98%,
respectively when compared to RNA detection (34), that is why
it would probably be the most suitable definition for tumoral
HPV-association in clinical routine.
â Most centers determine the HPV status in a carcinoma of
unknown primary (CUP): low LOC (60%).
In 6/10 centers, HPV status is routinely determined in lymph
node metastases without evidence of a primary tumor.
Cervical lymph node metastases from clinically undetectable
primary squamous cell carcinoma present a diagnostic and
therapeutic challenge. There is no clear consensus for the optimal
treatment in CUP. Recommendations range from surgery of the
neck alone to primary radiotherapy of the mucosa at risk and
both neck sides (35–39). In the era of treatment de-intensification,
the potential benefit of radiotherapy of putative primary tumor
sites has to be weighed against its detrimental effect on quality of
life and additional toxicity. The role of high-risk HPV infection
in the development of HNSCC has gained evidence (40, 41), in
particular for CUP. Several studies showed a high correlation
between HPV-positive lymph node metastases and the detection
of the primary tumor in the oropharynx. Many HPV-associated
tumors present with prominent nodal disease and small, difficult
or even undetectable (clinically and radiologically) primaries
hidden in palatine and lingual tonsillar crypts (42). Therefore,
a rising incidence of HPV-positive lymph node metastases
manifesting as CUP has been reported (43–46). Unfortunately
the sensitivity of 18FDG-PET/CT is adversely affected by false
positives from hypermetabolic oropharyngeal lymphoid tissue
(42). Even in patients with CUP HPV-positivity in lymph
node metastases is a positive prognostic factor and influencing
treatment decisions (47). This was accounted for in the updated
8th edition of the UICC classification by integrating HPV-
positivity of the primary tumor or the lymph node metastases
in CUP staging. Since the survey was performed prior to the
release of the 8th edition of the UICC TNM classification system
it is interesting to see, that at that time the importance of
HPV infection in CUP was not evident in 40% of the centers
in Switzerland.
After an intensive literature search in Pubmed and Medline
we have only found one comparable survey about patterns of
care for CUP. It has been performed recently in Germany, only
included radiation oncologists and has revealed that 82% of the
departments routinely determined HPV status in CUP (48). This
rate is significantly higher than in Switzerland. According to
the authors it is explained by the requirements to stage a CUP
according to the 8th TNM-classification edition and known as an
increasingly important prognostic factor.
â Determination of the HPV status in non-oropharyngeal
HNSCC is not accepted as a standard practice: no consensus.
HPV status is also determined in non-oropharyngeal primaries
in 4/10 centers.
This question is related to whether the presence of HPV in non-
oropharyngeal HNSCC represent viral-mediated carcinogenesis,
or merely a “bystander” infection and whether HPV-positivity
in such cases influences the treatment strategy and clinical
outcome (49). Large data on HPV DNA detection by PCR and
p16 expression in HNSCC biopsies suggests that the probability
of a cancer of the oral cavity, larynx, and hypopharynx being
attributable to HPV is at least 5-fold lower than that for OPSCC
(49, 50). High-risk HPV DNA was also detected in a significant
proportion of sinonasal, nasopharyngeal, and salivary gland
cancers, but the clinical significance of these findings in these
malignancies has not been clearly defined. Limited data on HPV
E6/E7 mRNA suggests that HPV-attributable HNSCC is rare in
the oral cavity (3%), larynx (7%) and lacking in the hypopharynx
(0%). Concerning the prognostic impact of HPV-positivity in
non-oropharyngeal subsites, no data currently supports that HPV
is significantly associated with improved outcome in oral or
laryngeal cancer (49), while data are lacking for other subsites
(49). In the absence of appropriately powered, well-designed
studies, HPV-detection in non-oropharyngeal sites does not seem
to impact staging or treatment.
â Most centers do not base their treatment decision on HPV
status: moderate LOC (80%).
HPV status does not influence the treatment decision in 8/10
centers. Two centers stated that they may consider changing the
treatment intensity.
Although HPV-positivity in OPSCC is an established positive
prognostic marker, treatment decisions should so far not be
influenced by it. There is a lot of ongoing discussion about
treatment de-escalation in this low-risk tumor but centers should
wait for the shortcoming results of prospective clinical trials to
decide on less intensive treatment regimen.
SUMMARY
In summary, there is no consensus regarding the applicability
of imaging findings indicating hypoxia as well as histological
differentiation grade. In all centers, the determination of the
HPV-status is a standard practice in oropharyngeal squamous cell
carcinoma rather than in cancer of unknown primary. Since the
survey was performed prior to the release of the 8th edition of
the UICC TNM classification system it is interesting to see, that
at that time the importance of HPV infection especially in CUP
was not evident in almost half of the centers in Switzerland.
Furthermore, there is a lack of standard method established
for the definition of HPV-status ranging from p16 IHC
as a single marker, HPV-DNA by PCR or ISH as single
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markers or the combination of both reflecting the lack of a
worldwide-accepted consensus for the accurate definition of
an HPV-driven cancer. In the majority of centers, there is no
therapeutic consequence of HPV-testing in both OPSCC and
CUP due to lack of practice guidelines based on prospective
clinical trials.
CONCLUSION
The findings of our survey indicate a low LOC among head
and neck oncologists working in academic and multidisciplinary
setting in 10 Swiss institutions. The highest LOC was achieved
among medical oncologists, whereas the lowest was observed
among head and neck surgeons. On the other hand, this level
of disagreement may also depend on the topics chosen for
the survey, and not necessarily the heterogeneity within the
disciplines. It is also interesting to witness a low LOC regarding
topics, where a high level of evidence actually does exist, and
vice versa. This article is expected to serve the head and neck
oncologists to be aware of their discrepancies and to stimulate
discussion toward standardization of practice and prioritize
topics of future clinical research.
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